The popularity of copyright’s blockbuster initially sparked a surge for major pharmaceutical companies, however recent changes present a complicated scenario for shareholders. Lower-cost alternatives are eroding revenue, and persistent litigation add additional complexity to the situation. While some companies could still benefit from complement… Read More